-
CEL-SCI Corporation Receives Final Government Approval from Taiwan to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer
Tuesday, May 3, 2011 - 9:20am | 110CEL-SCI Corporation (NYSE: CVM) announced today that the Department of Health, Taiwan has issued an approval letter that allows enrollment of patients to begin in Taiwan in the Phase III clinical trial of Multikine®. The approval letter was issued by the Department of Health after manufacturing...
-
J.P. Morgan Reiterates Overweight Rating On Dendreon
Tuesday, May 3, 2011 - 9:04am | 136According to J.P. Morgan, Dendreon (NASDAQ: DNDN) Overweight rating is reiterated. J.P. Morgan said that it reiterates its OW rating on DNDN and are providing follow-up thoughts post the company's 1Q conference call. “See our earlier Quick Take for our initial thoughts on quarterly performance....
-
Deutsche Bank Comments On Gilead Sciences Client Dinner
Tuesday, May 3, 2011 - 9:01am | 140According to Deutsche Bank, it met with Gilead Sciences (NASDAQ: GILD) management. Deutsche Bank said that it hosted a client dinner with COO John Milligan last night. “Co sees B-tripla as potentially being the "kindler gentler Atripla," with potential for uptake where Sustiva is not preferred....
-
Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Paving the Way for Sexual Equality for Women!
Tuesday, May 3, 2011 - 9:00am | 48Point Roberts WA, LINCOLNSHIRE, Ill. May 3, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, features an exclusive discussion with Mr. Stephen M. Simes, president and chief executive officer...
-
Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Paving the Way for Sexual Equality for Women!
Tuesday, May 3, 2011 - 9:00am | 48Point Roberts WA, LINCOLNSHIRE, Ill. May 3, 2011 - (Investorideas.com newswire.com) Investorideas.com, an investor research portal covering leading sectors including biotech stocks and pharma stocks, features an exclusive discussion with Mr. Stephen M. Simes, president and chief executive officer...
-
XOMA 3AB Enters Phase 1 Clinical Testing
Tuesday, May 3, 2011 - 8:50am | 127XOMA Ltd. (Nasdaq: XOMA) today announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has informed the Company that it is initiating a Phase 1 clinical trial for XOMA 3AB, XOMA's novel formulation of three antibodies designed to prevent...
-
NPS Pharma Reports 1Q EPS of $(0.13) vs. $(0.12) Estimate.
Tuesday, May 3, 2011 - 8:13am | 18NPS Pharma (NASDAQ: NPSP) Reports 1Q EPS of $(0.13) vs. $(0.12) Estimate.
-
Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today (DGX)
Tuesday, May 3, 2011 - 8:08am | 97Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary, has extended the expiration of its tender offer to acquire all outstanding shares of common...
-
Morgan Stanley Raises CELG Target To $55
Tuesday, May 3, 2011 - 8:02am | 27Morgan Stanley is raising its PT on share of Celgene Corporation (NASDAQ: CELG) to $55. Celgene Corporation closed Monday at $59.78.
-
Cytori Appoints Tommy G. Thompson to its Board; Names Lloyd Dean Chairman (CYTX)
Tuesday, May 3, 2011 - 7:50am | 82On April 28, 2011, Cytori Therapeutics (NASDAQ: CYTX) elected the Honorable Tommy G. Thompson, former Secretary of the US Department of Health & Human Services and Governor of Wisconsin, as an independent member of Cytori's Board of Directors. In addition, the Company's Board of Directors has...
-
QLT Announces Positive Results From Phase 1b Trial of QLT091001 in Subjects With Leber Congenital Amaurosis (QLTI)
Tuesday, May 3, 2011 - 7:30am | 160QLT Inc. (Nasdaq: QLTI) announced today positive preliminary results from its Phase 1b proof-of-concept clinical trial of QLT091001 for the treatment of Leber Congenital Amaurosis, a rare and disabling childhood blindness. Analysis of data from 12 subjects with LCA who were treated with QLT091001...
-
Deutsche Bank Comments On CELG Guidance Reiteration
Tuesday, May 3, 2011 - 7:25am | 102Celgene Corporation (NASDAQ: CELG) reiterated its '15 guidance of $8B in total revs & $8 in EPS, Deutsche Bank reports. “The company sees $6-6.5B revs coming from hematology business,” Deutsche Bank writes. “Revlimid will contribute towards 70%-80% of hematology sales. Abraxane '15 sales are...
-
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Tuesday, May 3, 2011 - 7:21am | 80Nile Therapeutics, Inc. (Nasdaq: NLTX) today announced dosing of the first patient in a Phase I clinical trial investigating the use of subcutaneous cenderitide. The trial is being conducted pursuant to Nile's previously announced collaboration with Medtronic and is the first clinical step...
-
Incyte Reports Q1 EPS of $(0.21) vs. $(0.32) Estimate; Revenues $32M vs. $19.51M Estimate (INCY)
Tuesday, May 3, 2011 - 7:08am | 22Incyte (NASDAQ: INCY) Reports Q1 EPS of $(0.21) vs. $(0.32) Estimate; Revenues $32M vs. $19.51M Estimate
-
Earnings Preview For Allergan (AGN, MRK, ISPH, VRX, CEPH)
Tuesday, May 3, 2011 - 4:25am | 456Allergan is expected to announce its Q1 earnings results on Wednesday, May 4, before the markets open. Analysts are predicting earnings per share to reach $0.74, up 13.8% on the last year's level of $0.65. Within the last 60 days, consensus estimate was lowered by $0.01. Revenues are projected to...